Marie Thibault
Stock Analyst
(3.96)
# 2,072
Out of 4,648 analysts
72
Total ratings
46.94%
Success rate
12.94%
Average return
Main Sectors:
Stocks Rated by Marie Thibault
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MASI Masimo | Maintains: Buy | $166 → $170 | $145.60 | +16.76% | 3 | Oct 14, 2024 | |
| PODD Insulet | Maintains: Buy | $250 → $260 | $236.87 | +9.77% | 3 | Oct 14, 2024 | |
| ESTA Establishment Labs Holdings | Maintains: Buy | $62 → $65 | $46.04 | +41.18% | 8 | Oct 14, 2024 | |
| BSX Boston Scientific | Maintains: Buy | $84 → $93 | $84.00 | +10.71% | 7 | Oct 14, 2024 | |
| HAE Haemonetics | Initiates: Buy | $112 | $72.26 | +55.00% | 1 | Sep 10, 2024 | |
| ATRC AtriCure | Maintains: Buy | $58 → $53 | $33.82 | +56.74% | 4 | Jul 31, 2024 | |
| DXCM DexCom | Maintains: Buy | $156 → $120 | $70.09 | +71.21% | 7 | Jul 26, 2024 | |
| XAIR Beyond Air | Downgrades: Neutral | n/a | $0.48 | - | 2 | Jun 25, 2024 | |
| VERO Venus Concept | Downgrades: Neutral | n/a | $0.43 | - | 3 | Oct 6, 2023 | |
| DCTH Delcath Systems | Maintains: Buy | $19 → $20 | $10.74 | +86.22% | 3 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $165 → $140 | $78.07 | +79.33% | 7 | Jun 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $4 → $3 | $1.73 | +73.41% | 3 | Mar 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $120 → $125 | $117.98 | +5.95% | 11 | Jan 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $100 → $97 | $48.83 | +98.65% | 3 | Oct 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $14.54 | - | 1 | Sep 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $7 | $1.77 | +295.48% | 1 | Jun 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.08 | - | 3 | Oct 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.34 | - | 1 | Jan 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 → $6 | $172.24 | -96.52% | 1 | Apr 9, 2020 |
Masimo
Oct 14, 2024
Maintains: Buy
Price Target: $166 → $170
Current: $145.60
Upside: +16.76%
Insulet
Oct 14, 2024
Maintains: Buy
Price Target: $250 → $260
Current: $236.87
Upside: +9.77%
Establishment Labs Holdings
Oct 14, 2024
Maintains: Buy
Price Target: $62 → $65
Current: $46.04
Upside: +41.18%
Boston Scientific
Oct 14, 2024
Maintains: Buy
Price Target: $84 → $93
Current: $84.00
Upside: +10.71%
Haemonetics
Sep 10, 2024
Initiates: Buy
Price Target: $112
Current: $72.26
Upside: +55.00%
AtriCure
Jul 31, 2024
Maintains: Buy
Price Target: $58 → $53
Current: $33.82
Upside: +56.74%
DexCom
Jul 26, 2024
Maintains: Buy
Price Target: $156 → $120
Current: $70.09
Upside: +71.21%
Beyond Air
Jun 25, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.48
Upside: -
Venus Concept
Oct 6, 2023
Downgrades: Neutral
Price Target: n/a
Current: $0.43
Upside: -
Delcath Systems
Aug 16, 2023
Maintains: Buy
Price Target: $19 → $20
Current: $10.74
Upside: +86.22%
Jun 8, 2023
Maintains: Buy
Price Target: $165 → $140
Current: $78.07
Upside: +79.33%
Mar 29, 2023
Maintains: Buy
Price Target: $4 → $3
Current: $1.73
Upside: +73.41%
Jan 26, 2023
Maintains: Buy
Price Target: $120 → $125
Current: $117.98
Upside: +5.95%
Oct 17, 2022
Maintains: Buy
Price Target: $100 → $97
Current: $48.83
Upside: +98.65%
Sep 8, 2022
Initiates: Neutral
Price Target: n/a
Current: $14.54
Upside: -
Jun 24, 2022
Maintains: Buy
Price Target: $9 → $7
Current: $1.77
Upside: +295.48%
Oct 13, 2021
Downgrades: Neutral
Price Target: n/a
Current: $1.08
Upside: -
Jan 21, 2021
Downgrades: Neutral
Price Target: n/a
Current: $0.34
Upside: -
Apr 9, 2020
Maintains: Buy
Price Target: $11 → $6
Current: $172.24
Upside: -96.52%